U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07239661) titled 'Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC' on Nov. 16.
Brief Summary: The aim of this study was to systematically evaluate the clinical efficacy and safety of electroacupuncture (EA) combined with PD-1 inhibitors in patients with advanced non-small cell lung cancer (NSCLC) who have an ECOG performance status of 2 through a multicenter, randomized, sham-controlled clinical trial. The core scientific question addressed in this study was whether EA combined with standard immunotherapy could further improve progression-free survival (PFS), immune function, and quality of life in these patients. Patients me...